Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLunglife Ai Regulatory News (LLAI)

  • There is currently no data for LLAI

Result of AGM

11 May 2022 15:17

RNS Number : 1544L
LungLife AI, INC
11 May 2022
 

 

LungLife AI, Inc. (the "Company" or "LungLife")

 

Result of Annual General Meeting

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a poll.

 

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

 

 Resolution

Votes for

%

Votes against

%

Votes withheld

Resolution 1 (Common)

TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2021 together with the directors' and auditor's reports thereon.

14,321,090

100

0

0

0

Resolution 2 (Common)

THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 3 (Common)

THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 4 (Common)

THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 5 (Common)

THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 6 (Common)

THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 7 (Common)

THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

Resolution 8 (Common)

THAT Crowe LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

14,321,090

100

0

0

0

 

As at 11 May 2022, there were 25,480,270 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

For further information please contact:

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

Via Walbrook PR

David Anderson, CFO

 

 

 

Investec Bank plc (Nominated Adviser & Broker)

Tel: +44 (0)20 7597 5970

Daniel Adams / Virginia Bull / Cameron MacRitchie

Walbrook PR Limited

 Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com

Paul McManus / Alice Woodings / Phillip Marriage

Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About Lunglife AI

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEALSFFFKAEFA
12
Date   Source Headline
29th May 20257:00 amRNSCancellation - LungLife AI, Inc.
27th May 20257:00 amRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
22nd May 20256:00 pmRNSLungLife AI
21st May 20257:01 amRNSHolding(s) in Company
21st May 20257:00 amRNSHolding(s) in Company
20th May 20255:15 pmRNSResult of Special Meeting
15th May 20257:00 amRNSHolding(s) in Company
15th May 20257:00 amRNSBlock listing Interim Review
14th May 20257:00 amRNSHolding(s) in Company
29th Apr 20257:00 amRNSNotice of Special Meeting
17th Apr 20257:00 amRNSLicense Agreement and Other Matters
10th Feb 20257:00 amRNSChange of Nominated Adviser and Joint Broker
3rd Feb 20257:00 amRNSOperational Update & Proposed Cancellation
19th Nov 20247:00 amRNSOperational update
15th Nov 20247:00 amRNSBlock listing Interim Review
25th Oct 20247:00 amRNSDirectorate Change
22nd Oct 20247:00 amRNSCancellation & Reissue Share Options, PDMR Notice
4th Oct 20247:00 amRNSOptions Cancellation and Re-issuance
2nd Oct 20247:00 amRNSLungLB® publication in peer-reviewed journal
2nd Sep 20247:00 amRNS-RData Supporting LungLB to be Presented at the AMP
22nd Aug 20247:00 amRNSHalf-year Report
16th Aug 20247:00 amRNSLCD coverage for Indeterminate Lung Nodules
15th Aug 20247:00 amRNSNotice of Results
5th Jun 20245:16 pmRNSResult of AGM
3rd Jun 202412:45 pmRNSConfirmation of AGM
15th May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20244:04 pmRNSHolding(s) in Company
25th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
17th Apr 20247:00 amRNSPresentation at NCI's EDRN Meeting
4th Apr 20247:00 amRNSPreliminary Audited Results
27th Mar 20247:00 amRNSNotice of Results
26th Mar 20241:49 pmRNSHolding(s) in Company
25th Mar 202410:33 amRNSHolding(s) in Company
22nd Mar 20249:39 amRNSAdmission of New Shares & PDMR Dealing
22nd Mar 20248:21 amRNSAdmission of New Shares & PDMR Dealing
21st Mar 20242:05 pmRNSResult of Special Meeting
6th Mar 20245:35 pmRNSPosting of Circular and Notice of Special Meeting
5th Mar 20247:00 amRNSResults of Placing and Subscription
4th Mar 20244:56 pmRNSProposed equity raise of approximately £1.8m
2nd Jan 20247:00 amRNSSuccessful validation study results for LungLB®
15th Nov 20237:00 amRNSBlock Listing Six Monthly Return
28th Sep 20237:00 amRNSClinical validation study update
14th Aug 20231:32 pmRNSDirector share purchases
8th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
6th Jun 20237:00 amRNSLungLB® study published in peer-reviewed journal
23rd May 20237:00 amRNSEnrolment completed for LungLB® validation study
15th May 20237:00 amRNSBlock Listing Six Monthly Return
4th May 20235:49 pmRNSResult of AGM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.